Previous 10 | Next 10 |
home / stock / cvac / cvac articles
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agr...
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financia...
Vaccine stocks have been on the fly ever since a never-before-seen bird flu strain started infecting people around the globe. On Thursday, a 59-yea...
U.S. stocks were mixed, with the Dow Jones index falling more than 100 points on Wednesday. Shares of Ollie’s Bargain Outlet Holdings, Inc. (...
Shares of XP Inc. (NASDAQ:XP) fell sharply during Wednesday's session after the company reported worse-than-expected first-quarter EPS results...
U.S. stocks were slightly lower, with the Dow Jones index falling around 10 points on Wednesday. Shares of Analog Devices, Inc. (NASDAQ:ADI) rose s...
U.S. stocks were mixed, with the Dow Jones gaining around 0.1% on Friday. Shares of Despegar.com, Corp. (NYSE:DESP) rose sharply during Friday'...
Tesla CEO Elon Musk does not seem to agree with Republicans at least on one thing. On Wednesday, the billionaire, true to his credentials as a tech...
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday. Shares of Spirit Airlines, Inc. (NYSE:SAVE) fell sharply duri...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...